Pfizer licenses gene for possible AMD therapy
New York-Pfizer Inc. has acquired the worldwide license to a novel human gene that could have the potential to treat neovascular age-related macular degeneration (AMD).
New York-Pfizer Inc. has acquired the worldwide license to a novel human gene that could have the potential to treat neovascular age-related macular degeneration (AMD).
Under the deal with Quark Biotech Inc., Pfizer will develop the gene, called RTP-801, and molecules that modify it, to treat wet AMD. Financial terms of the deal were not disclosed.
Quark Biotech, a Fremont, CA-based company with research facilities in Fremont and Israel, combines gene silencing and DNA microarray technology to identify target genes and proteins related to the cause or progression of a disease. It is working on potential treatments for dyslipidemia and fibrotic and ischemic diseases of the eye and kidneys, including diabetic retinopathy.
Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy
November 24th 2024In observance of Alzheimer Disease Awareness Month, held annually in November, we took a look back at the past year's news and expert insights in cell and gene therapy for Alzheimer disease.
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 21st 2024Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.
